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improved response due to the $5 incen-
tive was most pronounced for those
who did not respond to the prenotifica-
tion letter (1.46 (1.10, 1.92)) (Table 1).
In conclusion, we demonstrated that it
is possible to obtain DNA non-invasively
through the mail from a cohort of
children previously enrolled in a man-
dated postmarketing study that was not
initially designed to request or obtain a
biosample. We observed that an affirma-
tive response to a prenotification letter
significantly improves the likelihood of
obtaining DNA, that very few subjects
complain about a request for DNA, and
that it is still possible to obtain DNA from
individuals who had not indicated inter-
est in participation (non-responder). The
likelihood of obtaining DNA from the
PEER children was associated with the
severity of their atopic illness, as well as
other socioeconomic and demographic
factors (Table 1). However, the clinical
significance of these differences is not
known. Using a prenotification strategy
likely minimizes the cost per retrieved
sample (i.e., only send collection kits and
incentives to those who indicate interest
in participation). However, when re-
viewed from a study perspective, the
overall number of specimens received
from study participants (e.g., the overall
rate of response) is not remarkably
different based on a subject’s response
to a prenotification letter. From this
perspective, the rate of response when a
prenotification letter was returned was
about 12.2% (20.5% of the full sample
agreed to provide DNA via the prenoti-
fication letter times 59.6% of these
subjects who provided DNA), and was
12.7% for those who did not respond to
the initial letter. Ultimately, this cost
difference (i.e., sending $30 of materials
to the 674 responders vs sending materi-
als to all 3,264 PEER subjects) needs to
be considered with respect to the sample
size needed to conduct a study. Our
ultimate goal is to combine longitudinal
data currently collected from the PEER
study with data from our post hoc DNA
collection to better understand the influ-
ence of genetic factors on the natural
history of AD (Sandilands et al., 2006;
Sandilands et al., 2007). We encourage
others to use this technique to obtain
biological samples from the many other
FDA mandate phase IV studies of derma-
tological illnesses.
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TO THE EDITOR
Psoriasis is a chronic inflammatory skin
disease affecting approximately 2–3%
of the world population (Lowes et al.,
2007). Both epidermal and immuno-
logical functional defects are thought to
contribute to the disease pathogenesis
(Griffiths and Barker, 2007; Lowes
et al., 2007). In this regard, it is of
interest to note that the epidermal
expression of insulin-like growth factor
-binding protein 7 (IGFBP7) was found
to be decreased in psoriatic plaques as
compared with normal skin with photo-
therapy restoring IGFBP7 expression to
normal (Hochberg et al., 2007).
IGFBP7, a member of IGFBP super-
family, binds IGFs with low affinity, but
in contrast, recognizes insulin with a
high affinity, and thereby modifies its
metabolism, distribution, and ability to
bind to the insulin receptor (Yamanaka
et al., 1997). IGFBP7 has also IGF/
insulin-independent actions (Kato,
2000; Tamura et al., 2007). IGFBP7 is
expressed in an ubiquitous fashion in
normal tissues (Degeorges et al., 2000;
Lopez-Bermejo et al., 2003). IGFBP7
has been shown to regulate cell pro-
liferation, cell adhesion, cellular senes-
cence, apoptosis, and angiogenesis
in different cancer cell lines, and it is
therefore considered to function asAbbreviation: IGFBP7, insulin-like growth factor-binding protein 7
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tumor suppressor gene in numerous
cancers (Burger et al., 1998; Sato
et al., 2007; Wajapeyee et al., 2008).
As IGFBP7 expression was found
to be very low in psoriatic plaques
(Hochberg et al., 2007; Nousbeck
et al., 2010) and IGFBP7 was found
by us to regulate epidermal proces-
ses typically abnormally in psoriasis
(Nousbeck et al., 2010), we hypothe-
sized that IGFBP7 may have a role in
the development of the disease. To
substantiate this hypothesis, we studied
the role of IGFBP7 using a combination
of in vitro and in vivo assays. All
experiments using human materials
were conducted after receiving written
informed consent from the participants
according to a protocol reviewed and
approved by the Tel Aviv Sourasky
Medical Center Institutional Review
Board in accordance with the the
Declaration of Helsinki Principles. All
experiments using laboratory mice
were approved by the B Rappaport
Faculty of Medicine, Technion-Israel
Institute of Technology, institutional
committee on animal use.
First, to study IGFBP7 role during
epidermal differentiation in a physiolo-
gically relevant in vitro system, we used
stratifying three-dimensional epidermal
cell cultures (see Materials and Meth-
ods in Supplementary data online). In
this model system, keratinocytes are
grown at air–liquid interface on a
support consisting of collagen and
fibroblasts for up to 2 weeks. During
this time, keratinocytes fully differenti-
ate, forming a multilayered, cornified
epithelium that faithfully replicates
most physiological aspects of normal
epidermal biology (Poumay and
Coquette, 2007; Oji et al., 2010).
We initially confirmed histologically
the existence of a legitimate differentia-
tion program in these cultures (data
not shown). We then studied in
these cultures the effect of IGFBP7
downregulation, as found in psoriasis
(Nousbeck et al., 2010), on epidermal
homeostasis. Proliferating keratinocytes
were transfected with IGFBP7-specific
or control small interfering RNAs.
Transfected cells were then used to
generate skin equivalents. Punch biop-
sies were taken at 14 days of culture,
formalin-fixed, and processed for
hematoxylin and eosin and immuno-
staining (Figure 1a). IGFBP7-specific
small interfering RNA suppressed
IGFBP7 expression to o60% of the
level in skin equivalents transfected
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Figure 1. IGFBP7 downregulation in three-dimensional organotypic skin cultures induces a psoriasis-like phenotype. (a) Human primary keratinocytes
transfected with IGFBP7 small interfering RNA (siRNA) or control siRNA were used to generate skin equivalents. Punch biopsies were obtained at day 14 and
stained for hematoxylin and eosin (H&E; bar¼100 mm), KRT16, and KRT10 (bar¼50 mm). Note the strong expression of KRT16 in the suprabasal layers of skin
equivalents downregulated for IGFBP7. (b) Primary human keratinocytes were transfected with siRNA (IGFBP7 RNA interference (RNAi)) or a nonspecific siRNA
control (Co). RNA was extracted from skin equivalents at day 7 and analyzed by quantitative reverse transcriptase-PCR, normalized to b-actin, and expressed as
a percent of control. Data shown represent mean values±SD of three independent experiments performed in triplicate. (c) Epidermal and cornified layer
thickness were measured in three-dimensional organotypic skin cultures derived from keratinocytes transfected with control siRNA or IGFBP7-specific.
Epidermal and cornified layer thickness were measured at 15 randomly selected locations of three independent experiments. Results are provided as mean
values±SD. (*Po0.05 by Student’s t-test.) (d) Sections obtained at day 14 from skin equivalents derived from keratinocytes transfected with control or
IGFBP7-specific siRNA were stained for ERK and phosphorylated ERK (pERK; bar¼50 mm).
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with control small interfering RNA, as
measured at day 7 after transfection
(Figure 1b). We observed that down-
regulation of IGFBP7 expression was
associated with abnormal stratification,
marked hyperkeratosis, and acanthosis of
the skin equivalent models (Figure 1a),
which are all characteristically featured
in psoriasis. Quantitative morphometric
analysis of whole-epidermal and
cornified layer thickness confirmed
these observations (Figure 1c). In line
with these data, KRT16 (a marker of
epidermal proliferation) expression was
also found to be increased in skin
equivalents downregulated for IGFBP7
(Figure 1a), as characteristically re-
ported in lesional skin in psoriasis.
Furthermore, Ki67-positive cells were
significantly more numerous in IGFBP7-
downregulated models (1.8±1.42
positive cells per mm length) as com-
pared with control skin equivalents
(0.08±0.27 positive cells per mm length;
P-valueo0.0005). In contrast, KRT10
expression was decreased in IGFBP7-
deficient models as compared with con-
trol skin equivalent, as seen in psoriatic
skin versus normal skin (Figure 1a).
To ascertain the effect of IGFBP7
downregulation on the MAPK pathway,
which was reported to be involved in
the pathogenesis of psoriasis (Takahashi
et al., 2002) and to be regulated by
IGFBP7 (Nousbeck et al., 2010), we
stained sections of skin equivalents for
ERK and phosphorylated ERK expres-
sion. As shown in Figure 1d, ERK
pattern of expression was similar in
control and IGFBP7-deficient skin
equivalents. In contrast, phosphory-
lated ERK staining, which is normally
found to be expressed preferentially
at the basal cell layer, was found in
IGFBP7-deficient skin equivalents to be
expressed in the suprabasal cell layers,
as typically seen in psoriatic skin
(Takahashi et al., 2002). In addition,
phosphorylated ERK staining intensity
was higher in skin sections derived
from skin equivalents downregulated
for IGFBP7. Thus, downregulation of
IGFBP7 in a three-dimensional human
skin equivalent induces a histopatholo-
gical phenotype reminiscent of psoriasis.
Given the role of IGFBP7 in the
regulation of a number of processes
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Figure 2. Recombinant IGFBP7 attenuates a psoriasis-like phenotype in a humanized mouse model of psoriasis. We assessed the effect of IGFBP7 on a
psoriasiform phenotype induced in human skin grafts, as described in the text. Grafts were treated 5 times a week for 2 weeks with phosphate-buffered saline
injection (PBS), DEX cream, or injections of recombinant IGFBP7 (rIGFBP7). The grafts were harvested from the three groups of mice, and paraffin-embedded
5-mm sections were stained for hematoxylin and eosin (H&E), Ki67, CD3, and CD56 expression (bar¼100 mm).
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critically abnormal in psoriasis (Nous-
beck et al., 2010), and in view of the
fact that IGFBP7 deficiency seems to
replicate some psoriasis-associated
histopathological features in vitro, we
reasoned that IGFBP7 might alleviate
the various epidermal abnormalities seen
in psoriasis. To examine the validity of
this hypothesis, we used a humanized
mouse model for psoriasis (see Materials
and Methods in Supplementary data
online). In this model, a psoriasis-like
phenotype is induced in normal skin
grafted onto beige-severe combined im-
munodeficient mice by intradermal injec-
tion of natural killer/T cells derived from
psoriatic patients (Gilhar et al., 2002).
To assess the potential role of
IGFBP7 in vivo, 2 weeks after natural
killer/T-cell injection (6 weeks after
human skin grafting), three groups of
mice were treated as follows: one group
of mice was injected five times a week
with phosphate-buffered saline; a
second group of mice was injected five
times a week with recombinant
IGFBP7; and a third group of mice,
was treated with dexamethasone (DEX)
cream applied 5 times a week on the
graft, as positive control (DEX is ex-
pected to attenuate inflammation in this
model). Each group included five mice,
and the treatment was performed for a
total of 10 days.
As expected, all the five mice treated
with phosphate-buffered saline displayed
typical psoriatic features on histology,
including epidermal hyperkeratosis and
parakeratosis, acanthosis, elongation of
rete ridges, and a dense mononuclear
infiltrate in the dermis (Figure 2). All
these characteristics were absent in the
all five mice treated with DEX (Figure 2).
Remarkably, in the group of mice treated
with rIGFBP7, three mice showed full
recovery and one mouse recovered
partially (E50% of the biopsy showed
a normal histology; Figure 2).
We then stained skin sections
derived from the various human skin
grafts for Ki67, a marker of cellular
hyperproliferation. As shown in Fig-
ure 2, Ki67 was found to be expressed
strongly throughout the epidermis of
mice treated with phosphate-buffered
saline, whereas its expression was
very weak in skin of mice treated
with DEX or recombinant IGFBP7. To
characterize the inflammatory infiltrate
in the skin, we examined the expres-
sion of CD3 and CD56, which mark
T lymphocytes and natural killer cells,
respectively, (Figure 2). Both markers
were found to be expressed strongly in
the dermis of phosphate-buffered saline-
injected grafts, but weakly in grafts
treated either with DEX or recombinant
IGFBP7. These findings suggest a possible
effect of IGFBP7 on both epidermal and
immune elements during psoriasis deve-
lopment.
In conclusion, our results substantiate
the notion that IGFBP7 is involved in the
pathogenesis of psoriasis and may repre-
sent a novel target for therapeutic inter-
vention in skin diseases associated with
epidermal hyperproliferation.
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